|Bid||5.35 x 1300|
|Ask||5.40 x 300|
|Day's Range||5.25 - 5.55|
|52 Week Range||4.05 - 15.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.71|
FREMONT, Calif., March 19, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced a license agreement with Knight Therapeutics, Inc. (GUD.TO) (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx's oral, first-in-class small molecule treatment that has completed Phase 3 development for irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second Phase 3 study for hyperphosphatemia.
The Fremont, California-based company said it had net income of 21 cents per share. The biotechnology company posted revenue of $42 million in the period. For the year, the company reported that its loss ...
Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ ...
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress ...
FREMONT, Calif., Feb. 12, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer of an early stage biotech start-up company based in San Diego. "Jeremy has been a tremendous asset to Ardelyx, and I am incredibily grateful for his many contributions to the company and our programs over the years," said Mike Raab, president and chief executive officer of Ardelyx. "My time with Ardelyx has been extremely rewarding, and I'm proud of the many accomplishments of this team," said Jeremy.
FREMONT, Calif., Feb. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb. 15, 2018 in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines.
Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Ardelyx and eMagin are examples of many potential outperformers that analysts are bullishRead More...
In order to select the right breakout stock one has to first calculate its support and resistance level. A support level is the lower bound for stock movements while a resistance level refers to the maximum price which it trades within over a considerable period. In other words, the demand for a stock is at its lowest at its support level, which means most traders are willing to sell it.
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
The most recent earnings release Ardelyx Inc’s (NASDAQ:ARDX) announced in September 2017 suggested that losses became smaller relative to the prrior year’s level as a result of recent tailwinds InvestorsRead More...
FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor page of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines.
FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). Of patients treated, 9.2 percent reported experiencing diarrhea, with only 1.7 percent of patients discontinuing treatment due to diarrhea. "We are very excited to see that tenapanor was so well-tolerated in patients treated for up to a year, resulting in minimal treatment discontinuations," said David P. Rosenbaum, Ph.D., chief development officer of Ardelyx.
Five Prime Therapeutics and Ardelyx can add profound upside to your portfolio. This is because the optimistic growth outlook for their profitability and returns make their high-growth potential appealing relativeRead More...
FREMONT, Calif., Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited (Fosun Pharma) providing Fosun Pharma with the exclusive rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia related to chronic kidney disease. Tenapanor is an investigational oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx. Under the terms of the agreement, Ardelyx will receive an upfront payment of $12 million and is eligible to receive additional milestones of up to $113 million, as well as tiered royalty payments on net sales ranging from the mid-teens to 20 percent.
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
FREMONT, Calif. and TOKYO, Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (ARDX) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, "Kyowa Hakko Kirin"), today announced that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan. Tenapanor is an oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx that is in Phase 3 development in the United States for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis.
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
FREMONT, Calif., Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having received feedback from the United States Food and Drug Administration (FDA) on the trial design. The company believes this will limit the commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675.
On a per-share basis, the Fremont, California-based company said it had a loss of 44 cents. Ardelyx shares have declined 61 percent since the beginning of the year. The stock has fallen 57 percent in the ...
FREMONT, Calif. , Nov. 7, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017 ...